RT Journal Article
T1 Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
A1 Maerevoet, Marie
A1 Zijlstra, Josee M
A1 Follows, George
A1 Casasnovas, Rene-Olivier
A1 Vermaat, J S P
A1 Kalakonda, Nagesh
A1 Goy, Andre
A1 Choquet, Sylvain
A1 Van Den Neste, Eric
A1 Hill, Brian
A1 Thieblemont, Catherine
A1 Cavallo, Federica
A1 De la Cruz, Fatima
A1 Kuruvilla, John
A1 Hamad, Nada
A1 Jaeger, Ulrich
A1 Caimi, Paolo
A1 Gurion, Ronit
A1 Warzocha, Krzysztof
A1 Bakhshi, Sameer
A1 Sancho, Juan-Manuel
A1 Schuster, Michael
A1 Egyed, Miklos
A1 Offner, Fritz
A1 Vassilakopoulos, Theodoros P
A1 Samal, Priyanka
A1 Ku, Matthew
A1 Ma, Xiwen
A1 Corona, Kelly
A1 Chamoun, Kamal
A1 Shah, Jatin
A1 Shacham, Sharon
A1 Kauffman, Michael G
A1 Canales, Miguel
K1 DLBCL
K1 Exportin-1
K1 SINE compounds
K1 Selinexor
AB Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of 
YR 2021
FD 2021-07-16
LK http://hdl.handle.net/10668/18206
UL http://hdl.handle.net/10668/18206
LA en
DS RISalud
RD Apr 6, 2025